On the stock market since 2006, it operates in the world of health and science. It has 655 employees. Now — the numbers.
This is an established company with proven profits.
Average growth of 13% a year over the last 4 years. Every year shown ended in profit.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly above the class average — a step short of the very top.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Sales are growing strongly for its sector.
The price is looking for direction — no strong breakout, no collapse.
No real weak spot in any of the five subjects — a balanced report card.
angles, checked one by one.
The 2 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades below its recent peak — about 13% off the top. A pullback, not a collapse.
The net profit margin is 23% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 16% a year on average.
There is $359.1M in the vault; even if every debt were paid off, $173.5M would remain.
The company’s market value is 40 times its annual profit. Even a small disappointment could hit the price hard.
On our five-subject report card, LMAT sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: LMAT is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s what that quality should cost.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.